ArticleSurgical neurology international2025
Fourth ventricular stenting in foramen magnum decompression for type 1 Chiari malformations with syringomyelia.
Article in Surgical neurology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chiari malformation type 1 (CM-1) with syringomyelia is a common craniocervical abnormality and in symptomatic patients, there is ongoing debate regarding the optimum surgical strategy for decompressing the foramen magnum. The placement of a fourth ventricular-subarachnoid stent is a novel approach intended to increase symptom response rates and decrease the need for revision surgery, particularly in complex cases. The aim of this study was to present a single-center experience on the safety and efficacy of this technique. Methods: A retrospective review was conducted of all CM-1 patients who underwent Foramen Magnum Decompression (FMD) + fourth ventricular stent between January 01, 2012, and September 20, 2022, at a single UK neurosurgical center. Patients were identified using a keyword search of the hospital's electronic medical records. Primary outcomes included syrinx size and neurological symptoms. Secondary outcomes included operative duration, length of stay, and number of revision procedures. Syrinx size was measured on axial T2 magnetic resonance imaging sequences. Results: 17 patients received a stent as part of their FMD. The use of a stent improved or resolved the radiological appearance of the syrinx in 16 (87.5%) patients with an average AP diameter reduction of 57% (-4.86 mm standard deviation: 3.32). Clinically, 8 (62%) patients reported complete or partial resolution of limb symptoms. Following stent-assisted FMD only, 2 patients (11.7%) required further decompressive surgery. Conclusion: This case series evaluates the use of a fourth ventricular stent as part of FMD for CM-1. The study demonstrates the efficacy of a stent with satisfactory radiological and clinical outcomes. The results support the use of fourth ventricular stenting as a useful adjunct in patients with complex obstruction of fourth ventricle outflow.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.